Role of ascorbic acid supplementation on prevention of olanzapine induced metabolic side effects in schizophrenic patients

Indian Journal of Public Health Research and Development

Volumn 2, Issue 1, 2011, Pages 12-16

  Ingole, Shahu ^a   Belorkar, N R ^b   Waradkar, Praveer ^b   Shrivastava, Meena ^b  

^a Smt Kashibai Navale Medical College   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Blood sugar; Lipid Profile; Olanzapine; Schizophrenia; Vitamin C

Indexed keywords

ASCORBIC ACID; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OLANZAPINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC DISORDER; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WEIGHT GAIN;

EID: 79960580694     PISSN: 09760245     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Stahl SM. Essential psychopharmacology neuroscientific basis and practical application. 2nd ed. Cambridge University Press; 2004.
2. American psychiatric association practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154:1-63.
3. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61(10):111-61.
4. Lieberman JA. Atypical antipsychotic drugs as a firstline treatment of schizophrenia: a rational and hypothesis. J Clin Psychiatry 1996; 57(11):68-71.
5. Farewell WR, Stump TE, Wang J, Tafesse E, L'Italien GL, Tierney, WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 2004; 19:1200-05.
6. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003; 23(8):1037-43.
7. Ganguli R, Brar JS, Ayrton Z. Weight gain over four months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research 2001; 49:261-67.
8. Koro CE, Fedder DO, L'Italien GL, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenia patients. Arch Gen Psychiatry 2002; 59:1021-26.
9. Dai S, McNeill JH. Ascorbic acid supplementation prevents hyperlipidemia and improves myocardial performance in streptozotocin-diabetic rats. Diabetes Res Clin Pract 1995; 27(1):11-18.
10. Vinson JA, Sheu-Ju Hu, Jan S, Stansk NM. A citrus extract plus ascorbic acid decreases lipids, lipid peroxides, lipoprotein oxidative susceptibility, and atherosclerosis in hypercholesterolemic hamsters J Agri Food Chem 1998; 46(4); 1453-59.
11. Flier JS, Flier EM. Obesity. In: Harrison¢s principles of internal medicine. 16th ed. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo, DL, Jameson JL. editors, New York: McGraw Hill, 2005, 1311-19.
12. Miskiewicz SJ. Quantitative estimation of glucose by GOD/POD method. Clin Chem 1973; 19:253-54.
13. Tarbutton PN, Gunter CR. Quantitative estimation of serum total cholesterol. Clin Chem 1974; 20:724-26.
14. Foosati P. Quantitative estimation of serum triglyceride. Clin Chem 1982; 28:2077-79.
15. Finley PR. Quantitative estimation of serum HDL cholesterol. Clin Chem 1978; 24:931-34.
16. Rifai N, Warnick GR. Lipids, lipoproteins, apolipoprotiens, and other cardiovascular risk factors. In: Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. Burtis CA, Ashwood ER, Bruns DE editors, An Imprint of Elseview, 2006:903-81.
17. Thara R, Padmavati R, Shrinivasan TN. Schizophrenia. The British Journal of Psychiatry 2004; 184:366-73.
18. Baldessarini RJ, Tarazi I. Pharmacotherapy of psychosis and mania. In: Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. Brunton LL, Lazo JS, Pasrker KL, editors, McGraw Hill, 2005, 1753-71.
19. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-95.
20. Conley RR, Mahmoud R. A randomized double blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158:765-74.
21. Garyfallos G, Dimelis D, Kouniakis P., Sidiropoulos N, Karastergiou A, Lavrentiadis G, et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. J European Psychiatry 2003; 18:320-21.
22. Lindenmayer JP, Czobar P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290-96.
23. Koro CE, Fedder DO, L'Italien GL, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenia patients. Arch Gen Psychiatry 2002; 59:1021-26.
24. Simon JA, Hudes ES. Relation of serum ascorbic acid to serum lipids and lipoproteins in US adults. Journal of the American College of Nutrition 1998; 17(3):250-55.
25. Vinson JA, Sheu-Ju Hu, Jan S, Stansk NM. A citrus extract plus ascorbic acid decreases lipids, lipid peroxides, lipoprotein oxidative susceptibility, and atherosclerosis in hypercholesterolemic hamsters. J Agri Food Chem 1998; 46(4); 1453-59.